Cyclacel Pharmaceuticals, Inc.
Monday, February 26, 2024
Cyclacel is a clinical-stage biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation, epigenetics and mitosis biology. The transcriptional regulation program is evaluating fadraciclib, a CDK2/9 inhibitor, and the epigenetic/anti-mitotic program plogosertib, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies. Our strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates that address oncology and hematology indications.
CEO/Top Company Official
Lead Product in Development
Fadraciclib (Oral CDK2 and CDK9 inhibitor, formerly CYC065) Plogosertib (Oral PLK1 inhibitor, formerly CYC140)
Development Phase of Primary Product
Number Of Unlicensed Products